Immunocore Holdings plc (IMCR) reported a second-quarter 2026 loss of 2 cents per share, wider than the Zacks Consensus Estimate of a 1 cent loss, and an improvement from a 20 cent loss in the prior year. Second-quarter revenues reached $115.9 million, an 18.3% year-over-year increase, driven by higher sales of its drug Kimmtrak (tebentafusp-tebn), surpassing the $114 million consensus estimate.
Kimmtrak generated $74.9 million in U.S. sales, $34.1 million in Europe, and $6.9 million in other international markets during Q2. U.S. sales rose 17% year-over-year, while combined European and international sales increased 21%. The company’s research and development expenses increased to $73.9 million, reflecting the advancement of three phase III clinical studies. As of June 30, 2026, Immunocore had cash and equivalents of $880.2 million, up from $844.9 million in March 2026.
The registrational phase III TEBE-AM study, which evaluates Kimmtrak against a control arm for advanced cutaneous melanoma, is nearing its enrollment target of 540 patients, with data expected by late 2026. Immunocore is also advancing its pipeline, including the phase III PRISM-MEL-301 study evaluating its candidate brenetafusp for advanced cutaneous melanoma.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
